Molecular Diagnostics Technologies

Molecular Diagnostics Technologies Limited was a biotechnology company specializing in the development and commercialization of advanced in-vitro diagnostic (IVD) technologies, primarily focused on Fluorescent In Situ Hybridization (FISH). The company's technology platform utilized fluorescently labeled DNA probes to detect chromosomal and gene abnormalities with high specificity and sensitivity, offering significantly faster results compared to traditional karyotyping. Its product portfolio included FISH probes and specialized analysis systems for applications in prenatal screening and oncology, such as the detection of the HER-2/neu gene for breast cancer therapy selection. In 2007, the company was acquired by China Medical Technologies for approximately $176.8 million to expand its diagnostic footprint in the Chinese market. Following the acquisition, its technologies were integrated into China Medical's broader diagnostic offerings for cancer and congenital disorder monitoring.